Abstract
Nitric oxide is a key second messenger in most tissues, where it is generated at low concentrations, predominantly by the catalytic action of two constitutively expressed isoforms of nitric oxide synthase (NOS). Both of these are found in tumours, but malignancy is also associated with the expression of high levels of the inducible isoform of NOS, which is responsible for generation of high NO´ concentrations, not associated with normal physiology. This has profound consequences for the aetiology and malignant progression of primary cancer and metastatic dissemination. It also ensures that tumour vasculature remains highly dilated, so maintaining the abnormally high growth rates, characteristic of malignant disease. This dependency on NO´ can be targeted therapeutically by administering NOS inhibitors to block NO´ production, so reducing the availability of metabolic substrates and slowing tumour growth. However, there is now clear evidence that the effects of NO´ in tumours are bimodal such that intermediate levels optimise tumour growth, and interventions to raise or lower NO´ concentrations can inhibit it. Concentrations in the high μM range generated by NOS gene therapy or NO´ donor drugs induce apoptosis in solid tumours in vivo and slow their growth dramatically. These interventions are also potent enhancers of the anticancer effects of cytotoxic chemotherapy, particularly with the anthracyclines and platinum compounds. There is also clear evidence for specificity against malignant compared with normal cells, associated with the specific generation of peroxynitrite. Recent clinical trials have demonstrated both the safety and efficacy of nitric oxide therapy against lung and prostate cancer.
Keywords: Cancer, nitric oxide, nitric oxide synthase, chemotherapy, peroxynitrite, apoptosis
Current Pharmaceutical Design
Title: Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy
Volume: 16 Issue: 4
Author(s): David Hirst and Tracy Robson
Affiliation:
Keywords: Cancer, nitric oxide, nitric oxide synthase, chemotherapy, peroxynitrite, apoptosis
Abstract: Nitric oxide is a key second messenger in most tissues, where it is generated at low concentrations, predominantly by the catalytic action of two constitutively expressed isoforms of nitric oxide synthase (NOS). Both of these are found in tumours, but malignancy is also associated with the expression of high levels of the inducible isoform of NOS, which is responsible for generation of high NO´ concentrations, not associated with normal physiology. This has profound consequences for the aetiology and malignant progression of primary cancer and metastatic dissemination. It also ensures that tumour vasculature remains highly dilated, so maintaining the abnormally high growth rates, characteristic of malignant disease. This dependency on NO´ can be targeted therapeutically by administering NOS inhibitors to block NO´ production, so reducing the availability of metabolic substrates and slowing tumour growth. However, there is now clear evidence that the effects of NO´ in tumours are bimodal such that intermediate levels optimise tumour growth, and interventions to raise or lower NO´ concentrations can inhibit it. Concentrations in the high μM range generated by NOS gene therapy or NO´ donor drugs induce apoptosis in solid tumours in vivo and slow their growth dramatically. These interventions are also potent enhancers of the anticancer effects of cytotoxic chemotherapy, particularly with the anthracyclines and platinum compounds. There is also clear evidence for specificity against malignant compared with normal cells, associated with the specific generation of peroxynitrite. Recent clinical trials have demonstrated both the safety and efficacy of nitric oxide therapy against lung and prostate cancer.
Export Options
About this article
Cite this article as:
Hirst David and Robson Tracy, Nitric Oxide in Cancer Therapeutics: Interaction with Cytotoxic Chemotherapy, Current Pharmaceutical Design 2010; 16 (4) . https://dx.doi.org/10.2174/138161210790232185
DOI https://dx.doi.org/10.2174/138161210790232185 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Non-coding RNAs from Microorganisms and their Therapeutic Use in the Treatment of Different Human Cancers
Current Gene Therapy Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes
Current Drug Metabolism Review of the Biological Activity of Maslinic Acid
Current Drug Targets CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Peptide-Mediated Cellular Delivery of Oligonucleotide-Based Therapeutics In Vitro: Quantitative Evaluation of Overall Efficacy Employing Easy to Handle Reporter Systems
Current Pharmaceutical Design Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Editorial (Thematic Issue: Nucleoside/tide Analogues in Modern Drug Design)
Current Medicinal Chemistry Androgen Receptor Coregulatory Proteins as Potential Therapeutic Targets in the Treatment of Prostate Cancer
Current Cancer Therapy Reviews Adopting Network Pharmacology for Cancer Drug Discovery
Current Drug Discovery Technologies The Relationship Between Prostate Cancer and Metformin Consumption: A Systematic Review and Meta-analysis Study
Current Pharmaceutical Design An Overview of Phytotherapeutic Approaches for the Treatment of Benign Prostatic Hyperplasia
Mini-Reviews in Medicinal Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Ontologies of Drug Discovery and Design for Neurology, Cardiology and Oncology
Current Pharmaceutical Design Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Strategies to Improve the Efficacy of Platinum Compounds
Current Medicinal Chemistry Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Novel Approaches in the Treatment of Antipsychotic-Induced Hyperprolactinemia: The Role of Partial Agonists of D2 Dopaminergic Receptors
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery